$225.65
Biogen is a drug manufacturers - general business based in the US. Biogen shares (BIIB) are listed on the NASDAQ and all prices are listed in US Dollars. Biogen employs 7,570 staff and has a trailing 12-month revenue of around $9.7 billion.
Our top picks for where to buy Biogen stock
How to buy Biogen stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – BIIB. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Biogen stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Biogen stock price (NASDAQ: BIIB)
Use our graph to track the performance of BIIB stocks over time.Biogen shares at a glance
Latest market close | $225.65 |
---|---|
52-week range | $189.44 - $282.74 |
50-day moving average | $223.21 |
200-day moving average | $233.55 |
Wall St. target price | $281.57 |
PE ratio | 28.0763 |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $8.00 |
Is it a good time to buy Biogen stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Biogen price performance over time
Historical closes compared with the close of $225.65 from 2024-07-05
1 week (2024-06-28) | |
---|---|
1 month (2024-06-07) | |
3 months (2024-04-05) | |
6 months (2024-01-05) |
1 year (2023-07-07) | |
---|---|
2 years (2022-07-07) | |
3 years (2021-07-07) | 355.33 |
5 years (2019-07-05) | 234.25 |
Is Biogen stock undervalued or overvalued?
Valuing Biogen stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Biogen's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Biogen's P/E ratio
Biogen's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 28x. In other words, Biogen shares trade at around 28x recent earnings.
That's comparable to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29).
Biogen's PEG ratio
Biogen's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 6.2424. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Biogen's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Biogen's EBITDA
Biogen's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $2.5 billion.
The EBITDA is a measure of a Biogen's overall financial performance and is widely used to measure a its profitability.
Biogen financials
Revenue TTM | $9.7 billion |
---|---|
Operating margin TTM | 27.28% |
Gross profit TTM | $7.9 billion |
Return on assets TTM | 4.86% |
Return on equity TTM | 8.05% |
Profit margin | 12.07% |
Book value | $104.49 |
Market Capitalization | $32.7 billion |
TTM: trailing 12 months
Biogen share dividends
We're not expecting Biogen to pay a dividend over the next 12 months.
Have Biogen's shares ever split?
Biogen's shares were split on a 3:1 basis on 17 January 2001. So if you had owned 1 share the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Biogen shares – just the quantity. However, indirectly, the new 66.7% lower share price could have impacted the market appetite for Biogen shares which in turn could have impacted Biogen's share price.
Biogen share price volatility
Over the last 12 months, Biogen's shares have ranged in value from as little as $189.44 up to $282.74. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biogen's is -0.038. This would suggest that Biogen's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Biogen has bucked the trend.
Biogen overview
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc. ; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.
Frequently asked questions
What percentage of Biogen is owned by insiders or institutions?Currently 0.158% of Biogen shares are held by insiders and 93.101% by institutions. How many people work for Biogen?
Latest data suggests 7,570 work at Biogen. When does the fiscal year end for Biogen?
Biogen's fiscal year ends in December. Where is Biogen based?
Biogen's address is: 225 Binney Street, Cambridge, MA, United States, 02142 What is Biogen's ISIN number?
Biogen's international securities identification number is: US09062X1037 What is Biogen's CUSIP number?
Biogen's Committee on Uniform Securities Identification Procedures number is: 449370105
More guides on Finder
-
Best broker cash sweep rates for July 2024
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
-
6 best bitcoin ETFs to easily invest in bitcoin through your broker
We analyzed a number of bitcoin ETFs to determine which are best to invest in.
-
11 best trading platforms for beginners [July 2024]
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
-
6 best ETF brokers for low-cost fund investing [July 2024]
Check out our picks of the best ETF brokers for beginners, options trading, micro-investing and more.
-
5 best international stock brokers to invest in foreign assets
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
-
9 best discount brokers for low-cost trading and investing [July 2024]
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
-
9 best robo-advisors for affordable, automated portfolio management
Check out our picks of the best robo-advisors for new and experienced investors alike.
-
12 best stock apps of July 2024 to elevate your mobile trading
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
-
11 best brokerage accounts of July 2024: Top picks for investors
Check out our picks of the best brokerage accounts for beginners, micro-investing, crypto trading and more.
-
How to invest $50K for growth, passive income and diversification
There are many ways to invest and grow $50K depending on your financial situation, personal needs and goals.
Ask a Question